6L9.F Stock Surges 2400% in May 2026 After-Hours Trading on XETRA

ViewRay, Inc. (6L9.F) is experiencing an extraordinary surge in after-hours trading on XETRA today. The medical device manufacturer’s stock has skyrocketed 2400%, reaching €0.025 per share with trading volume hitting 3,500 shares—a massive 1,254% increase versus the 279-share average. This dramatic move reflects intense market activity in the healthcare sector. The company, headquartered in Oakwood, Ohio, specializes in MRI-guided radiation therapy systems for cancer treatment. We’re tracking this volatile movement as investors reassess the stock’s fundamentals and market positioning.

Understanding the 6L9.F Stock Price Explosion

The €0.025 price point represents a historic rally from the €0.001 opening level today. This 2,400% intraday gain marks one of the most dramatic moves we’ve seen in medical device stocks. The day’s range stretched from €0.001 to €0.025, capturing the full volatility arc.

However, context matters here. ViewRay’s 52-week high sits at €4.60, meaning today’s price remains 99.5% below that peak. The stock has declined 99.25% over the past year, suggesting this bounce may represent profit-taking or short-covering rather than fundamental improvement. Track 6L9.F on Meyka for real-time updates on this volatile movement.

Market Sentiment: Trading Activity and Liquidation Signals

Trading volume tells a compelling story about market behavior. The 3,500 shares traded today dwarfs the typical 279-share average volume, indicating concentrated interest from specific investors. This relative volume spike of 1,254% suggests either institutional repositioning or retail attention following the stock’s extreme decline.

The after-hours session amplifies volatility since fewer market participants trade during these hours. Bid-ask spreads widen, and price discovery becomes less efficient. ViewRay’s negative fundamentals—including a -€0.55 earnings per share and -105% net profit margin—suggest this rally lacks earnings support. The company continues burning cash with -€0.51 operating cash flow per share, raising questions about sustainability.

Financial Health and Valuation Metrics

ViewRay’s financial position reveals significant challenges beneath today’s price surge. The company carries a €207.2 million market cap with 8.29 billion shares outstanding, creating substantial dilution. The price-to-sales ratio of 2.37 appears reasonable on the surface, but profitability metrics paint a darker picture.

Key concerns include a debt-to-equity ratio of 1.05, meaning liabilities exceed shareholder equity. The current ratio of 2.36 provides some liquidity cushion, but negative cash flow generation raises concerns about runway. With €0.75 cash per share and ongoing losses, the company faces pressure to achieve profitability or secure additional financing. The -0.85 return on equity confirms value destruction for shareholders.

Meyka AI Grade and Investment Outlook

Meyka AI rates 6L9.F with a grade of C+, suggesting a HOLD recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score of 57.87 out of 100 reflects mixed signals: the company operates in the growing healthcare sector but faces profitability headwinds.

The medical device industry remains attractive long-term, with MRI-guided radiation therapy representing innovation in cancer treatment. However, ViewRay must demonstrate revenue growth and path to profitability. These grades are not guaranteed and we are not financial advisors. The extreme volatility today should not distract from fundamental challenges requiring management execution and market adoption of their MRIdian technology.

Final Thoughts

ViewRay’s 2400% after-hours surge on XETRA captures market attention but masks deeper financial challenges. The €0.025 price remains far below historical levels, and negative cash flow continues pressuring the balance sheet. While the medical device sector offers growth potential, 6L9.F requires significant operational improvements before justifying higher valuations. Today’s volume spike may reflect short-covering or speculative trading rather than fundamental catalysts. Investors should focus on quarterly earnings reports, revenue trends, and cash burn rates rather than daily price swings. The company’s ability to commercialize MRIdian technology and reach profitability will det…

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.